Company's VP of Scientific Oversight to present AMDL's Onko-Sure(TM) in vitro diagnostic cancer test to conference attendees TUSTIN, Calif., July 22 /PRNewswire-FirstCall/ -- AMDL Diagnostics Inc., a wholly-owned subsidiary of AMDL Inc. (NYSE Alternext US: ADL), announced today its Vice President of Scientific Oversight of AMDL Diagnostics Inc. is presenting at this year's AACC Annual Meeting and Clinical Lab Expo in Chicago, IL. Dr. Andrea Small-Howard will introduce AMDL's non-invasive Onko-Sure(TM) in vitro (IVD) diagnostic blood test to conference attendees that include clinical laboratory professionals, physicians, research scientists, and other individuals involved with clinical chemistry and related disciplines. AMDL's Onko-Sure IVD diagnostic test enables physicians and their patients to effectively monitor and/or detect solid tumor cancers, including CRC, by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products. With the exception of heart disease, cancer causes more deaths than any other medical condition in the world. According to the World Health Organization (WHO), cancer is rapidly becoming the leading cause of death worldwide and is expected to overtake heart disease by 2010. As the third most common cancer worldwide and the second leading cause of cancer deaths irrespective of gender in the US, CRC is one of the most commonly diagnosed of all cancers. Last year, there were approximately 151,000 new cases diagnosed in the US, roughly 51,000 deaths due to the disease*, and almost half of all patients thought to be "cured" are expected to develop a recurrence of CRC within 5 years - usually due to undetected metastases.** Frequent surveillance of diagnosed patients is recommended. Onko-Sure is researched, developed and manufactured in AMDL Diagnostic's Tustin, California-based facilities and sold to 3rd party distributors, which then sell directly to CLIA-certified reference laboratories in the US as well as clinical reference labs, hospital labs and physician-operated labs in the international market. The test is approved by the US Food and Drug Administration (US FDA) for the monitoring of CRC in the US and by Health Canada as a lung cancer detection and monitoring tool. In addition the test is approved in Europe, where it has obtained the CE mark approval, and Taiwan, South Korea, India, and Vietnam as a general cancer screen. According to AMDL Chairman and CEO Mr. Douglas MacLellan, "Since AMDL Diagnostics began commercializing its Onko-Sure IVD cancer test we've seen substantive market demand both as a CRC monitoring test and a pan tumor cancer screen. This is positive news for the Company in that selling Onko-Sure in the US as a CRC monitoring test and expanding the application of the test as a pan tumor marker internationally offers greater market penetration and revenue upside. On tests sold to IVD distributors ranging from $50 per test per patient for CRC and up to $150-$250 per test per patient as a pan tumor screen we expect a gross profit margin above 90%. Our top priority is to continue signing strategic distributor partners that will enable us to achieve our market share targets." The AACC Annual Meeting is an industry-leading event held for the international scientific/medical society of clinical laboratory professionals, physicians, research scientists and other individuals involved with clinical chemistry and related disciplines. It offers hundreds of educational sessions including plenary sessions, Symposia; Meet the Experts sessions, Chair's Invited sessions, and the Poster sessions that cover a wide variety of topics. The Clinical Lab Expo is the exhibition tradeshow aspect of the AACC Annual Meeting where many of the industry's leading vendors have an opportunity to present to conference attendees. Attendees wishing to meet with AMDL to learn more about AMDL's Onko-Sure IVD cancer test can visit the McCormick Place Convention Center located at 2301 S. Lake Shore Drive, Chicago, IL 60616. Physicians, patients, and any other interested parties who have an interest in ordering AMDL Diagnostic's Onko-Sure IVD cancer test should contact . For AMDL Investor Relations information contact Kristine Szarkowitz at or 1.206.310.5323. *National Cancer Institute: Cancer Facts and Figures 2008. **Bull World Health Organ: Shike M, Winawer SJ, Greenwald PH, et al. About AMDL: Headquartered in Tustin, CA with operations in China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The Company employs over 510 people in the U.S. and China. Forward Looking Statements: Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. AMDL Contact: Kristine Szarkowitz Director-Investor Relations (Tel :) 206.310.5323 DATASOURCE: AMDL, Inc. CONTACT: Kristine Szarkowitz, Director-Investor Relations of AMDL, Inc., +1-206-310-5323,

Copyright